

#20

PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	09/621,593
Filing Date	July 21, 2000
First Named Inventor	de Groot et al.
Group Art Unit	1635
Examiner Name	B. Whiteman
Attorney Docket Number	2183-44971 IS

RECEIVED

OCT 25 2002

TECH CENTER 1600/2900

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		de Groot et al., Over-expression of the murine polymeric immunoglobulin receptor gene in the mammary gland of transgenic mice, Transgenic Research, 1999, pp. 125-135, Vol. 8, The Netherlands.	
PW		Tan et al., Bovine alpha-s1-casein gene sequences direct expression of variant of human tissue plasminogen activator in the milk of transgenic mice, www.ncbi.nlm.nih.gov, printed 10/17/2002. <i>abstract only</i>	
		Kim et al., High-level expression of human lactoferrin in milk of transgenic mice using genomic lactoferrin sequence, www.ncbi.nlm.nih.gov, printed 10/17/2002. <i>abstract only</i>	
		Bijvoet et al., Recombinant human acid alpha-glucosidase: high level production in mouse milk, biochemical characteristics, correction of enzyme deficiency in GSDII KO mice, Human Molecular Genetics, 1998, pp. 1815-1824, Vol. 7, No. 11, Oxford University Press.	
		Yarus et al., Production of active bovine tracheal antimicrobial peptide in milk of transgenic mice, Proc. Natl. Acad. Sci., November 1996, pp. 14118-14121, Vol. 93.	
		Hyttinen et al., High-level expression of bovine beta-lactoglobulin gene in transgenic mice, Journal of Biotechnology, 1998, pp. 191-198, Vol. 61.	
		Theuer et al., Angiotensin II induced inflammation in the kidney and in the heart of double transgenic rats, www.pubmedcentral.nih.gov, printed 10/17/2002. <i>pages 1-16</i>	
		Ju et al., Conditional and targeted overexpression of vascular chymase causes hypertension in transgenic mice, PNAS, June 19, 2001, pp. 7469-7474, Vol. 98, No. 13.	
		Takahashi et al., The milk protein promoter is a useful tool for developing a rat with tolerance to a human protein, Transgenic Research, 2001, pp. 571-575, Vol. 10, Kluwer Academic Publishers, The Netherlands.	
		Kulseth et al., Cloning and characterization of two forms of bovine polymeric immunoglobulin receptor cDNA, www.ncbi.nlm.nih.gov, printed 10/17/2002. <i>abstract only</i>	
PW		Fujiwara et al., Analysis of control elements for position-independent expression of human alpha-lactalbumin YAC, www.ncbi.nlm.nih.gov, printed 10/17/2002. <i>abstract only</i>	

Examiner
Signature*Brian Williams*

Date


Considered

11/15/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	09/621,593
Filing Date	July 21, 2000
First Named Inventor	de Groot et al.
Group Art Unit	1635
Examiner Name	B. Whiteman
Attorney Docket Number	2183-4497LIS

RECEIVED**OCT 25 2002****TECH CENTER 1600/2900****OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
Bv		Brink, et al., Developing Efficient Strategies for the Generation of Transgenic Cattle which Produce Biopharmaceuticals in milk, Theriogenology, 2000, pp. 139-148, Vol. 53, Elsevier Science Inc.	
		Van Berkel et al., Large scale production of recombinant human lactoferrin in the milk of transgenic cows, www.nature.com, printed 6/26/2002. <i>abstract pp. 484-487</i>	
		Hirabayashi et al., A comparative study on the integration of exogenous DNA into mouse, rat, rabbit and pig genomes, www.ncbi.nlm.nih.gov, printed 10/17/2002. <i>abstract only</i>	
		Hyttinen et al., High-level expression of bovine beta-lactoglobulin gene in transgenic mice, www.ncbi.nlm.nih.gov, printed 10/17/2002. <i>abstract only</i>	
		Gutierrez et al., Expression of a bovine kappa-CN cDNA in the mammary gland of transgenic mice utilizing a genomic milk protein gene as an expression cassette, www.ncbi.nlm.nih.gov, printed 10/17/2002. <i>abstract only</i>	
Bw		Cerdan et al., Accurate spatial and temporal transgene expression driven by a 3.8-kilobase promoter of the bovine beta-casein gene in the lactating mouse mammary gland, www.ncbi.nlm.nih.gov, printed 10/17/2002. <i>abstract only</i>	

Examiner
Signature*B. Whiteman*Date
Considered*11/15/02*

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.